Janux Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Janux Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.63M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($68.99M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($58.29M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($63.06M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($32.67M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($6.78M) | Mar 18, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($157.67M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($98.85M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($72.98M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($67.09M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($32.93M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($4.84M) | Mar 18, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $68.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $54.92M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $53.44M | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | $26.24M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $3.04M | Mar 18, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($82.24M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($43.81M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($50.58M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($42.92M) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | ($16.98M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($4.37M) | Mar 18, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $359.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.85M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $6.45M | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | $1.48M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 18, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $380.41M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $364.01M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $379.82M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $16.22M | Mar 18, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.74M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $38.74M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $36.06M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $43.27M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $13.50M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $9.23M | Mar 18, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $956.82M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $344.35M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $320.74M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $366.33M | Feb 27, 2025 |
| FY2022 | Dec 31, 2020 | ($14.64M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | ($7.94M) | Mar 18, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($351.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($237.76M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($168.76M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($110.47M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($47.41M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($14.74M) | Mar 18, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $430.61M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $19.21M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $51.43M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $35.58M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $7.81M | Mar 18, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | (1) | Mar 10, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | (1) | Mar 10, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 60.38M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 59.06M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 46.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 41.62M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 41.24M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 1.05M | Mar 18, 2022 |